FDA Fast-Tracks First-Ever Treatment for Rare Muscle Disease LGMD2I/R9

BridgeBio’s BBP-418 receives FDA Priority Review with a November 27, 2026 PDUFA date. If approved, it would be the first therapy for LGMD2I/R9 and any form of limb-girdle muscular dystrophy.